Yurday Öncül
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yurday Öncül has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Kadir Arslan
Department of Biostatistics and Medical Informatics, Inonu University Faculty of Medicine, Malatya, Türkiye
1 shared publication - Ahmet Taner Elmas
Division of Pediatric Nephrology, Department of Pediatrics, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
1 shared publication Arzu Akyay
Department of Pediatric Hematology and Oncology, Inonu University School of Medicine, Malatya, Turkey
1 shared publication- Arzu Akyay
İnönü University, Faculty of Medicine, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Malatya, Türkiye
1 shared publication - Arzu Akyay
Department of Pediatric Hematology and Oncology, Faculty of Medicine, Inönü University, Malatya, Turkey
1 shared publication - Bengü Macit
Department of Pediatric Hematology and Oncology, Malatya Training and Research Hospital, 44000 Malatya, Türkiye
1 shared publication
Latest Publications
- Open Access
- 10 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7810
Renal Complications After Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
Background/Objectives: Kidney-related complications contribute substantially to morbidity in children undergoing hematopoietic stem cell transplantation (HSCT), although evidence in pediatric populations remains limited. This study aimed to evaluate the incidence of acute kidney injury (AKI), chronic kidney disease (CKD), and hypertension within the first two years following HSCT and to investigate factors associated with these complications. Methods: We retrospectively analyzed 70 pediatric patients who underwent HSCT at the İnönü University Pediatric Bone Marrow Transplantation Unit between November 2017 and December 2023; patients who died during follow-up were excluded. Renal function was assessed using serum creatinine, the glomerular filtration rate was measured by 24-h urine collection or estimated using the Schwartz formula, and renal imaging was performed. The Acute Kidney Injury Network criteria were used to classify AKI, whereas CKD was defined according to the Kidney Disease Outcomes Quality Initiative criteria. Associations with demographic characteristics, primary disease, conditioning regimen, nephrotoxic drug exposure, graft-versus-host disease, veno-occlusive disease, and infections were evaluated. Results: AKI occurred in 54.3% of patients during the first 100 days, comprising stage 1 in 30.0%, stage 2 in 17.1%, and stage 3 in 7.1%. Primary diagnosis, conditioning regimen, nephrotoxic drug use, and transplantation-related complications were not significantly associated with AKI. Hypertension developed in 32.9% of patients, with most cases occurring during the early period after transplantation. A significant association was observed between hypertension and myeloablative conditioning without total body irradiation (p = 0.014). CKD was present in 45.7% of evaluated patients at month 6 and 44.6% at month 12. Amphotericin B use was significantly associated with CKD at month 6 (p = 0.015). No patient developed end-stage kidney disease or required dialysis. Conclusions: Renal complications were common after pediatric HSCT. AKI occurred frequently during the first 100 days, while CKD remained prevalent at 6 and 12 months. Younger age and amphotericin B exposure were associated with CKD in this cohort. Early recognition of renal injury and long-term kidney follow-up are warranted after pediatric HSCT.
- 10 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7810
Open AccessRenal Complications After Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
Background/Objectives: Kidney-related complications contribute substantially to morbidity in children undergoing hematopoietic stem cell transplantation (HSCT), although evidence in pediatric populations remains limited. This study aimed to evaluate the incidence of acute kidney injury (AKI), chronic kidney disease (CKD), and hypertension within the first two years following HSCT and to investigate factors associated with these complications. Methods: We retrospectively analyzed 70 pediatric patients who underwent HSCT at the İnönü University Pediatric Bone Marrow Transplantation Unit between November 2017 and December 2023; patients who died during follow-up were excluded. Renal function was assessed using serum creatinine, the glomerular filtration rate was measured by 24-h urine collection or estimated using the Schwartz formula, and renal imaging was performed. The Acute Kidney Injury Network criteria were used to classify AKI, whereas CKD was defined according to the Kidney Disease Outcomes Quality Initiative criteria. Associations with demographic characteristics, primary disease, conditioning regimen, nephrotoxic drug exposure, graft-versus-host disease, veno-occlusive disease, and infections were evaluated. Results: AKI occurred in 54.3% of patients during the first 100 days, comprising stage 1 in 30.0%, stage 2 in 17.1%, and stage 3 in 7.1%. Primary diagnosis, conditioning regimen, nephrotoxic drug use, and transplantation-related complications were not significantly associated with AKI. Hypertension developed in 32.9% of patients, with most cases occurring during the early period after transplantation. A significant association was observed between hypertension and myeloablative conditioning without total body irradiation (p = 0.014). CKD was present in 45.7% of evaluated patients at month 6 and 44.6% at month 12. Amphotericin B use was significantly associated with CKD at month 6 (p = 0.015). No patient developed end-stage kidney disease or required dialysis. Conclusions: Renal complications were common after pediatric HSCT. AKI occurred frequently during the first 100 days, while CKD remained prevalent at 6 and 12 months. Younger age and amphotericin B exposure were associated with CKD in this cohort. Early recognition of renal injury and long-term kidney follow-up are warranted after pediatric HSCT.
- 23 September 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 246, 108571
Risk factors for acute symptomatic seizure in children with cerebral sinovenous thrombosis: Experience from a tertiary center
- 23 September 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 246, 108571
Risk factors for acute symptomatic seizure in children with cerebral sinovenous thrombosis: Experience from a tertiary center
- 5 May 2023
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 91 (7) , 696-701
Thromboembolism in Children
Objective To study pediatric patients who were diagnosed with thrombosis between January 2009 and March 2020. Methods Patients were evaluated with respect to thrombophilic risk factors, localization of the thrombus, response to treatment, and recurrence rates during the last 11 y. Results Among 84 patients, 59 (70%) had venous thrombosis and 20 (24%) had arterial thrombosis. The number of documented thrombosis amongst hospitalized children in authors’ hospital has increased over the years. It has been observed that the annual incidence of thromboembolism has increased after 2014. Thirteen patients were recorded between 2009 and 2014 and 71 patients between 2015 and 2020 (until March 2020). Exact thrombosis localization could not be detected in 5 patients. The median age of patients was 8 ± 5.95 (range 0–18). Fourteen children (16.9%) had a history of familial thrombosis. Genetic and/or acquired risk factors were detected in 81 (96.4%) of the patients. Overall, 64 patients (76.1%) had acquired risk factors such as infection (20.2%), catheterization (13.1%), liver disease (11.9%), mastoiditis (8.3%), liver transplantation (6%), hypoxic-ischemic encephalopathy (4.8%), dehydration (3.6%), trauma (3.6%) and cancer (2.4%). As genetic risk factors, the most common genetic mutations were PAI-1 4G>5G, MTHFR C677T, and MTHFR A1298C mutations. Twenty-eight (41.2%) patients had at least one genetic thrombophilic mutation. At least one homozygous mutation in 37 patients (44%) and at least one heterozygous mutation in 55 patients (65.4%) were detected. Conclusions The annual incidence of thrombosis has increased over the years. Genetic predisposition and acquired risk factors play an important role in etiology, treatment, and follow-up in children with thromboembolism. Especially, genetic predisposition is common. Thrombophilic risk factors should be investigated and optimal therapeutic and prophylactic measures should be promptly taken in children with thrombosis.
- 5 May 2023
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 91 (7) , 696-701
Thromboembolism in Children
Objective To study pediatric patients who were diagnosed with thrombosis between January 2009 and March 2020. Methods Patients were evaluated with respect to thrombophilic risk factors, localization of the thrombus, response to treatment, and recurrence rates during the last 11 y. Results Among 84 patients, 59 (70%) had venous thrombosis and 20 (24%) had arterial thrombosis. The number of documented thrombosis amongst hospitalized children in authors’ hospital has increased over the years. It has been observed that the annual incidence of thromboembolism has increased after 2014. Thirteen patients were recorded between 2009 and 2014 and 71 patients between 2015 and 2020 (until March 2020). Exact thrombosis localization could not be detected in 5 patients. The median age of patients was 8 ± 5.95 (range 0–18). Fourteen children (16.9%) had a history of familial thrombosis. Genetic and/or acquired risk factors were detected in 81 (96.4%) of the patients. Overall, 64 patients (76.1%) had acquired risk factors such as infection (20.2%), catheterization (13.1%), liver disease (11.9%), mastoiditis (8.3%), liver transplantation (6%), hypoxic-ischemic encephalopathy (4.8%), dehydration (3.6%), trauma (3.6%) and cancer (2.4%). As genetic risk factors, the most common genetic mutations were PAI-1 4G>5G, MTHFR C677T, and MTHFR A1298C mutations. Twenty-eight (41.2%) patients had at least one genetic thrombophilic mutation. At least one homozygous mutation in 37 patients (44%) and at least one heterozygous mutation in 55 patients (65.4%) were detected. Conclusions The annual incidence of thrombosis has increased over the years. Genetic predisposition and acquired risk factors play an important role in etiology, treatment, and follow-up in children with thromboembolism. Especially, genetic predisposition is common. Thrombophilic risk factors should be investigated and optimal therapeutic and prophylactic measures should be promptly taken in children with thrombosis.